サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737542

バレット食道の世界市場

Barrett's Esophagus

出版日
ページ情報
英文 274 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.71円
バレット食道の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 274 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バレット食道の世界市場は2030年までに61億米ドルに達する見込み

2024年に49億米ドルと推定されるバレット食道の世界市場は、2024～2030年の分析期間にCAGR 3.9%で成長し、2030年には61億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロトンポンプ阻害剤は、CAGR 2.9%を記録し、分析期間終了時には24億米ドルに達すると予測されます。H2受容体拮抗薬セグメントの成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 6.9%で成長予測

米国のバレット食道市場は、2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と2.9%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界のバレット食道市場- 主要動向と促進要因まとめ

なぜバレット食道は胃食道疾患管理の臨床的・商業的注目を集めるのか？

バレット食道（BE）は、食道腺がんの前駆症状としての役割が確立されているため、消化器ヘルスケアにおける焦点となりつつあります。胃食道逆流症（GERD）の有病率の上昇、肥満、喫煙、高齢化に伴い、BEの診断数は世界的に増加しており、より積極的なサーベイランスと治療戦略が必要とされています。この疾患は食道粘膜の異常な変質を特徴とし、その同定は悪性腫瘍を予防するための早期介入に不可欠です。

医療界は、リスクのある患者に対するルーチンの内視鏡的スクリーニングを提唱し、組織学的分類を治療の指針に取り入れるよう、臨床ガイドラインを強化して対応しています。このような進歩により、BEをめぐる診断・治療市場はより構造化されつつあり、早期発見と効果的な切除療法によって患者の予後を大幅に改善し、長期的ながんの負担を軽減することができます。

診断と治療における技術革新はどのようにバレット食道治療の範囲を広げているのか？

内視鏡による画像診断と組織サンプリングの技術的改良により、バレット食道の早期かつ正確な診断が可能になってきています。高精細白色光内視鏡、ナローバンドイメージング、共焦点レーザー内視鏡、体積レーザー内視鏡はサーベイランスの基準を再定義し、異形成変化をより詳細に可視化しています。一方、Cytospongeや分子バイオマーカーパネルのような内視鏡検査以外の選択肢も、プライマリケアで実施可能な費用対効果が高く、スケーラブルなスクリーニングツールとして台頭してきています。

治療面では、ラジオ波焼灼療法（RFA）、凍結療法、および内視鏡的粘膜切除術（EMR）が、疾患の退縮と長期寛解という有望な結果を得て、異形成BEに対する主流のアプローチになりつつあります。これらの治療法は食道切除術に代わるより低侵襲な治療法であり、消化器専門クリニックや大規模外来センターでの採用が進んでいます。異形成グレード、病変の特徴、患者の併存疾患に基づいた個別化された治療アルゴリズムの開発は、BEを管理されモニターされる疾患状態としてさらに定着させ、診断-治療統合プラットフォームへの需要を生み出しています。

バレット食道市場はどこで拡大し、誰がその拡大を推進しているのか？

北米が世界のBE市場をリードしており、これは体系化されたスクリーニングプログラム、GERDに対する認識の広まり、内視鏡治療に対する償還制度に支えられています。欧州は標準化された臨床プロトコールと集中登録によって疾患の追跡とサーベイランスを強化しています。アジア太平洋は、特に日本、韓国、オーストラリアの都市部に新たなビジネスチャンスをもたらしており、そこではGERD罹患率の上昇と高度な内視鏡機能の採用がBE治療の連続性を拡大しています。

主な利害関係者には、早期診断と治療を推進する消化器専門医、腫瘍専門医、内視鏡専門医が含まれます。多科目病院、消化器病センター、外来内視鏡検査室は、病理検査やバイオマーカーに基づく診断を提供する検査室ネットワークに支えられた中心的なケア提供拠点です。医療技術企業、分子診断薬開発企業、内視鏡技術開発に重点を置く研修機関は、市場浸透を拡大し、地域間の臨床熟練度を維持する上で重要な役割を果たしています。

バレット食道市場の長期的成長の原動力は？

バレット食道市場の長期的な成長は、疫学的、技術的、政策的な要因によって支えられています。GERDの負担の増加とBE-がんの進行リスクに対する一般市民や医師の意識の高まりが、定期的なスクリーニングと早期介入の需要を高めています。医療システムは積極的なBE管理による食道がん予防の費用対効果を認識しており、低侵襲診断やアブレーションソリューションの普及を促しています。

新しい画像診断および治療ツールの規制当局による承認と、診断および治療プラットフォームのバンドル化に対する業界の努力により、治療パスウェイが合理化されつつあります。レジストリを介した分野横断的な連携とデータ共有により、転帰の透明性とエビデンスに基づく意思決定が強化されています。ヘルスケアが精密医療と価値に基づくケアに向かう中、重大な疑問が浮上しています。BE市場は、早期発見と個別化された介入戦略の統合を継続し、世界なケア環境において拡張可能で費用対効果の高いがん予防を実現できるだろうか？

セグメント

薬剤クラス（プロトンポンプ阻害薬、H2受容体拮抗薬、粘膜保護薬、その他の薬剤クラス別）、流通チャネル（病院薬局、小売薬局、オンライン薬局）

調査対象企業の例（注目の34社）

  • AbbVie Inc.
  • Abbott Laboratories
  • Addex Therapeutics Ltd.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Castle Biosciences
  • Cipla Inc.
  • Cook Medical Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Limited
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33540

Global Barrett's Esophagus Market to Reach US$6.1 Billion by 2030

The global market for Barrett's Esophagus estimated at US$4.9 Billion in the year 2024, is expected to reach US$6.1 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Proton Pump Inhibitors, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the H2 Receptor Antagonists segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.9% CAGR

The Barrett's Esophagus market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Barrett's Esophagus Market - Key Trends & Drivers Summarized

Why Is Barrett’s Esophagus Gaining Clinical and Commercial Attention in Gastroesophageal Disease Management?

Barrett’s Esophagus (BE) is becoming a focal point in gastrointestinal healthcare due to its established role as a precursor to esophageal adenocarcinoma. With the rising prevalence of gastroesophageal reflux disease (GERD), obesity, smoking, and aging populations, the number of BE diagnoses is increasing globally, necessitating more proactive surveillance and treatment strategies. This condition is marked by the abnormal transformation of the esophageal lining, and its identification is critical for early intervention to prevent malignancy.

Medical communities are responding with heightened clinical guidelines advocating routine endoscopic screening for at-risk individuals and incorporating histological grading to guide care pathways. These advancements are fostering a more structured diagnostic and therapeutic market around BE, where early detection and effective ablation or resection therapies can significantly improve patient outcomes and reduce long-term cancer burden-positioning Barrett’s Esophagus as a clinically actionable and commercially viable disease segment in digestive health management.

How Are Innovations in Diagnostics and Therapeutics Expanding the Scope of Barrett’s Esophagus Treatment?

Technological improvements in endoscopic imaging and tissue sampling are enhancing the early and accurate diagnosis of BE. High-definition white light endoscopy, narrow-band imaging, confocal laser endomicroscopy, and volumetric laser endomicroscopy are redefining surveillance standards, offering more detailed visualization of dysplastic changes. Meanwhile, non-endoscopic options like the Cytosponge and molecular biomarker panels are emerging as cost-effective, scalable screening tools that can be administered in primary care settings.

On the therapeutic front, radiofrequency ablation (RFA), cryotherapy, and endoscopic mucosal resection (EMR) are becoming mainstream approaches for dysplastic BE, with promising outcomes in disease regression and long-term remission. These interventions offer less invasive alternatives to esophagectomy and are driving adoption in both specialized GI clinics and high-volume ambulatory centers. The development of personalized therapy algorithms based on dysplasia grade, lesion characteristics, and patient comorbidities is further anchoring BE as a managed, monitored disease state-creating demand for integrated diagnostic-therapeutic platforms.

Where Is the Market for Barrett’s Esophagus Expanding, and Who Are the Key Stakeholders Driving Uptake?

North America leads the global BE market, supported by structured screening programs, widespread GERD awareness, and reimbursement coverage for endoscopic therapies. Europe follows with standardized clinical protocols and centralized registries enhancing disease tracking and surveillance. Asia-Pacific presents emerging opportunities, especially in urban centers across Japan, South Korea, and Australia, where rising GERD incidence and adoption of advanced endoscopic capabilities are expanding the BE care continuum.

Key stakeholders include gastroenterologists, oncologists, and endoscopy specialists who drive early diagnosis and treatment. Multispecialty hospitals, digestive disease centers, and outpatient endoscopy units are central care delivery hubs, supported by laboratory networks offering pathology and biomarker-based diagnostics. Medtech firms, molecular diagnostics developers, and training organizations focused on endoscopic skill development play critical roles in scaling market penetration and sustaining clinical proficiency across regions.

What Is Driving Long-Term Growth in the Barrett’s Esophagus Market?

Long-term growth in the Barrett’s Esophagus market is underpinned by a confluence of epidemiological, technological, and policy drivers. Increasing GERD burden, combined with greater public and physician awareness of BE-cancer progression risks, is elevating demand for routine screening and early intervention. Health systems are recognizing the cost-effectiveness of preventing esophageal cancer through proactive BE management, prompting wider adoption of minimally invasive diagnostics and ablation solutions.

Regulatory endorsements of new imaging and therapeutic tools, coupled with industry efforts to bundle diagnostic and treatment platforms, are streamlining the care pathway. Cross-disciplinary collaboration and data-sharing via registries are enhancing outcome transparency and evidence-based decision-making. As healthcare moves toward precision medicine and value-based care, a critical question emerges: Can the BE market continue to integrate early detection with personalized intervention strategies to deliver scalable, cost-effective cancer prevention across global care settings?

SCOPE OF STUDY:

The report analyzes the Barrett's Esophagus market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents, Other Drug Classes); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Abbott Laboratories
  • Addex Therapeutics Ltd.
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Castle Biosciences
  • Cipla Inc.
  • Cook Medical Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Limited
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Barrett's Esophagus - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising GERD Prevalence Drives Demand for Early Screening and Diagnosis of Barretts Esophagus
    • Advancements in Endoscopic Imaging and Biopsy Tools Improve Detection Accuracy
    • High-Risk Patient Monitoring Through Surveillance Programs Fuels Use of Specialized Devices
    • Minimally Invasive Treatment Modalities Like RFA and Cryotherapy Expand Therapeutic Reach
    • Clinical Guidelines Emphasize Early Intervention to Prevent Progression to Esophageal Adenocarcinoma
    • Biomarker Research Enhances Risk Stratification and Personalized Surveillance Protocols
    • Growing Awareness of Barretts Risk Factors Spurs Referrals From Primary Care to GI Specialists
    • EHR Integration and Registry Participation Improve Patient Tracking and Longitudinal Outcomes
    • AI-Based Image Analysis Tools Support Enhanced Detection in Diagnostic Endoscopy
    • Device Manufacturers Focus on Comfort, Precision, and Workflow Efficiency in Diagnostic Kits
    • Health System Adoption of Barretts Pathways Improves Standardization of Care Delivery
    • Expansion of Digestive Health Programs in Hospitals Elevates Focus on Esophageal Precancers
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Barrett's Esophagus Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Barrett's Esophagus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Barrett's Esophagus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Barrett's Esophagus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Proton Pump Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Proton Pump Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for H2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for H2 Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for H2 Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mucosal Protective Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mucosal Protective Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mucosal Protective Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Barrett's Esophagus by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Barrett's Esophagus by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Barrett's Esophagus by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Barrett's Esophagus by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Barrett's Esophagus by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Barrett's Esophagus by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Barrett's Esophagus by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Barrett's Esophagus by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Barrett's Esophagus by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Barrett's Esophagus by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Barrett's Esophagus by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Barrett's Esophagus by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Barrett's Esophagus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Barrett's Esophagus by Drug Class - Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Barrett's Esophagus by Drug Class - Percentage Breakdown of Value Sales for Proton Pump Inhibitors, H2 Receptor Antagonists, Mucosal Protective Agents and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Barrett's Esophagus by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Barrett's Esophagus by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION